TY - JOUR
T1 - Comparison of pancreaticoduodenectomy and bile duct resection for middle bile duct cancer
T2 - A multi-center collaborating study of Japan and Korea
AU - Hayashi, Hiroki
AU - Jang, Jin Young
AU - Kim, Kyung Sik
AU - Choi, Jin Sub
AU - Takahara, Takeshi
AU - Choi, Sung Hoon
AU - Hirano, Satoshi
AU - Yu, Hee Chul
AU - Uemura, Syuichiro
AU - Unno, Michiaki
N1 - Publisher Copyright:
© 2020 The Authors. Journal of Hepato-Biliary-Pancreatic Sciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Hepato-Biliary-Pancreatic Surgery
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Background: It is currently unknown whether bile duct segmental resection (BDSR) is an acceptable method for localized middle bile duct cancer (mid-BDC) when R0 resection can be achieved. This study aimed to investigate the short- and long-term outcomes of mid-BDC patients treated with pancreaticoduodenectomy (PD) compared to those for BDSR. Methods: This was a retrospective, Japanese and Korean multi-center collaboration study based on patients' medical records. Results: A total of 663 patients, including 245 BDSR and 418 PD cases, were enrolled. The incidence of postoperative pancreatic fistula (3.3% vs 44.1%, P <.0001), surgical site infection in the organ space (6.1% vs 17.7%, P <.0001) and clinically problematic morbidities (15.9% vs 32.8%, P <.0001) was significantly higher in the PD group. There was no difference in the mortality rate (0.8% vs 1.7%, P =.3566). Local (33.9% vs 14.4%, P <.0001) and lymph node (22.4% vs 11.0%, P <.0001) recurrence rates were significantly higher in the BDSR group. Relapse-free survival (25.0 vs 34.0 months, P =.0184) and overall survival (41.2 vs 60.1 months, P =.0019) were significantly longer in the PD group. The PD group had significantly better prognosis in stage IA/IB cases (58.3 vs 111.5 months, P =.0067), which were the best indicators for BDSR, even when R0 resection was achieved. In multivariate analysis, BDSR was an independent poor prognostic factor. Conclusion: Despite the inferior perioperative short-term outcomes, our data advocate that PD should be the standard procedure for mid-BDCs and that BDSR should be avoided even if R0 resection can be achieved. (UMIN000017914).
AB - Background: It is currently unknown whether bile duct segmental resection (BDSR) is an acceptable method for localized middle bile duct cancer (mid-BDC) when R0 resection can be achieved. This study aimed to investigate the short- and long-term outcomes of mid-BDC patients treated with pancreaticoduodenectomy (PD) compared to those for BDSR. Methods: This was a retrospective, Japanese and Korean multi-center collaboration study based on patients' medical records. Results: A total of 663 patients, including 245 BDSR and 418 PD cases, were enrolled. The incidence of postoperative pancreatic fistula (3.3% vs 44.1%, P <.0001), surgical site infection in the organ space (6.1% vs 17.7%, P <.0001) and clinically problematic morbidities (15.9% vs 32.8%, P <.0001) was significantly higher in the PD group. There was no difference in the mortality rate (0.8% vs 1.7%, P =.3566). Local (33.9% vs 14.4%, P <.0001) and lymph node (22.4% vs 11.0%, P <.0001) recurrence rates were significantly higher in the BDSR group. Relapse-free survival (25.0 vs 34.0 months, P =.0184) and overall survival (41.2 vs 60.1 months, P =.0019) were significantly longer in the PD group. The PD group had significantly better prognosis in stage IA/IB cases (58.3 vs 111.5 months, P =.0067), which were the best indicators for BDSR, even when R0 resection was achieved. In multivariate analysis, BDSR was an independent poor prognostic factor. Conclusion: Despite the inferior perioperative short-term outcomes, our data advocate that PD should be the standard procedure for mid-BDCs and that BDSR should be avoided even if R0 resection can be achieved. (UMIN000017914).
KW - bile duct segmental resection
KW - extrahepatic cholangiocarcinoma
KW - middle bile duct cancer
KW - pancreaticoduodenectomy
UR - http://www.scopus.com/inward/record.url?scp=85081318999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081318999&partnerID=8YFLogxK
U2 - 10.1002/jhbp.724
DO - 10.1002/jhbp.724
M3 - Article
C2 - 32048467
AN - SCOPUS:85081318999
SN - 1868-6974
VL - 27
SP - 289
EP - 298
JO - Journal of Hepato-Biliary-Pancreatic Sciences
JF - Journal of Hepato-Biliary-Pancreatic Sciences
IS - 6
ER -